Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates

分组1 - Bolt Biotherapeutics reported a quarterly loss of $3.84 per share, better than the Zacks Consensus Estimate of a loss of $4.3, and improved from a loss of $7.6 per share a year ago, resulting in an earnings surprise of +10.70% [1] - The company achieved revenues of $2.5 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 150.00%, compared to zero revenues a year ago [2] - The stock has underperformed, losing about 24.5% since the beginning of the year, while the S&P 500 declined by only 1% [3] 分组2 - The earnings outlook for Bolt Biotherapeutics is uncertain, with current consensus EPS estimates of -$4.21 on $1.5 million in revenues for the coming quarter and -$12.51 on $3.5 million in revenues for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 36% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8] - The estimate revisions trend for Bolt Biotherapeutics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]